CClinicalTrials.gg
RecruitingNCT07631767SHAPEUpdated Aug 20, 2026

Shift Workers' Health Behavior Action Program Across Europe

An interventional study of Combined Lifestyle Intervention in Night Shift Work, Obesity & Overweight and Circadian Misalignment, sponsored by Wageningen University. Recruiting at 5 sites in 3 countries. Open to participants aged 21 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by Wageningen University · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Study summary

This study evaluates the effects of a Combined Lifestyle Intervention Program (CLIP) on sleep, lifestyle behaviors, obesity risk and health in night-shift workers. The primary objective is to assess the effect of the CLIP on objectively measured sleep duration. Secondary objectives include behavioral outcomes related to sleep, diet, physical activity, and stress, as well as body weight and metabolic outcomes, . It is hypothesized that CLIP participants will show a greater increase in sleep duration than controls, alongside favorable changes in lifestyle and health outcomes.

02

Conditions studied

  • Night Shift Work
  • Obesity & Overweight
  • Circadian Misalignment

Keywords

  • Lifestyle
  • Stress
  • Sleep
  • Diet
  • Physical Activity
03

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Age ≥ 21 years
  • Work ≥ 24 hours per week
  • Shift work duration > 3 years and currently doing night shifts
  • Expected to continue night shiftwork for at least 1 year after inclusion
  • On average working ≥ 4 night shifts per month
  • Working generally ≥ 2 consecutive night shifts
  • In possession of a smartphone and willing to download the study application

Exclusion criteria

Exclusion Criteria:

  • Body Mass Index (BMI) \< 18.5 or > 40 kg/m2
  • Pregnant or lactating
  • Chronic diseases with ongoing therapy (e.g. renal failure, active hepatitis, cirrhosis, myocardial infarction, chronic obstructive pulmonary disease and cancer)
  • Current or recent use of medications interfering with sleep, including: Central nervous system stimulants (e.g., Ritalin, Adderall, Modafinil or similar); Chronic use of sleep agents (e.g., benzodiazepine, non-hypnotic benzodiaze-pine, first-generation antihistamine, melatonin receptors agonists or similar); Other medications or combinations significantly affecting sleeping patterns
  • Recent or ongoing psychotherapy for sleep disorders
  • Current or recent use of medications affecting appetite or weight regulation, including: Appetite-enhancing/weight-gain medications (e.g., atypical antipsychotics, cor-ticosteroids such as prednisone, mirtazapine or similar); Appetite-suppressing/weight-loss medications (e.g., CNS stimulants such as Ritalin, Adderall, GLP-1 receptors agonists or similar); Other medications or combinations significantly influencing appetite or body weight
  • Participation in another human trial, lifestyle program or weight loss intervention within the past 3 months
  • Planned surgical procedure during the study period
  • History of or planned bariatric surgery/treatment
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
400 participants (estimated)

Study arms

  • Experimental
    Intervention

    Intervention group receives access to the 24-week combined lifestyle intrevention, which includes the mobile intervention app and four interactive workshops.

    Behavioral: Combined Lifestyle Intervention

  • No intervention
    Control

    The control group receives informational brochures with general advice on the four life-style domains, without active behavioral support. The control group receives access to the combined lifestyle intrevention after the intervention period has ended.

Interventions

  • BehavioralCombined Lifestyle Intervention

    The 24-week lifestyle intervention is structured in four 6-week blocks focusing on sleep and stress management or diet and physical activity. Lifestyle advice and behavior change techniques are delivered via a mobile application, complemented by workshops.

05

What researchers measure

Primary outcomes

  1. Sleep duration

    Total sleep time (min/24h)

    Time frame: From enrollment to the end of intervention (24 weeks)

Secondary outcomes

  1. Body weight

    (kg)

    Time frame: From enrollment to end of intervention (24 weeks)

  2. BMI

    (kg/m2)

    Time frame: From enrollment to end of intervention (24 weeks)

  3. Objective sleep quality

    Wake after sleep onset (min spent awake/main sleep episode), derived from actigraphy data

    Time frame: From enrollment to end of intervention (24 weeks)

  4. Overall diet quality

    Diet quality score: Eetscore™, a 55-item FFQ which is scored with the Dutch Healthy Diet 2015-index to evaluate adherence to the Dutch food-based dietary guideline; resulting in a total score between zero (no adherence) and 100 (complete adherence).

    Time frame: From enrollment to end of intervention (24 weeks)

  5. Physical activity level

    Light, moderate, vigorous activity (min), Sedentary time (min) as measured with an actigraphy (Motionwatch)

    Time frame: From enrollment to end of intervention (24 weeks)

  6. Perceived stress

    Perceived stress score (PSS-10), a 10-item validated questionnaire assessing the extent to which individuals perceive their lives as unpredictable, uncontrollable, and overloaded. Items are rated on a 5-point Likert scale referring to experiences over the past month; higher score mean more stress.

    Time frame: From enrollment to end of intervention (24 weeks)

  7. Subjective sleep quality (Insomina)

    Insomnia severity (0-28): a 7-item self-administered questionnaire validated in shift workers as a proxy for sleep quality. Items assess the severity of insomnia symptoms, including difficulties with sleep onset, maintenance, and early awakening. Each item is scored 0-4, with total scores ranging from 0 to 28; higher scores indicate more severe insomnia

    Time frame: From enrollment to end of intervention (24 weeks)

  8. Subjective leep quality (pattern)

    Shift Work Disorder Questionnaire (SWDQ): a 4-item questionnaire assessing sleep patterns, excessive sleepiness, and functional impairment related to shift work (53). Each item is scored 1-4, yielding a total score of 4-16, with higher scores reflecting greater symptom severit

    Time frame: [Time Frame: From enrollment to end of intervention (24 weeks)]

  9. Chrono-nutrition patterns

    Meal timing, frequency, regularity; using the Chrono nutrition Questionnaire for Shift Workers (CNQ-Shift). The questionnaire contains 20-23 questions, five questions each for morning, afternoon, and night shifts, three split shifts questions (if applicable), and two questions for work-free days.

    Time frame: From enrollment to end of intervention (24 weeks)

  10. Food preferences

    FFPQ (liking/wanting scores): Participants rate "how pleasant it would be to try a bite of this food," using a 100-point visual analogue scale (explicit liking). A forced choice procedure is then carried used to assess which food participants would "most like to eat now" (implicit wanting).

    Time frame: From enrollment to end of intervention (24 weeks)

  11. Occupational physical activity

    OSPAQ (min)

    Time frame: From enrollment to end of intervention (24 weeks)

  12. Work-related sense of coherence

    Work-related sense of coherence Work-Soc (5-point Likert scale), a 9-scale assessing individuals' perceived comprehensibility, manageability, and meaningfulness at work.

    Time frame: From enrollment to end of intervention (24 weeks)

  13. Satisfaction With Life

    Satisfaction With Life Scale (SWLS): a 5-item questionnaire evaluating global life satisfaction (66). Items are rated on a 7-point scale

    Time frame: [Time Frame: From enrollment to end of intervention (24 weeks)]

Other outcomes

  1. Body composition

    body Fat percentage (%) measured with bio-impedance analysis (BIA)

    Time frame: From enrollment to end of intervention (24 weeks)

  2. waist to hip circumference

    ratio of waist and hip circumference (cm/cm)

    Time frame: [Time Frame: From enrollment to end of intervention (24 weeks)]

  3. Behavior assessment

    Action planning, Coping planning, Habit formation, Intention. All items are scored on a either a 5 or 7-point Likert scale ranging from totally disagree to totally agree.

    Time frame: From enrollment to end of intervention (24 weeks)

  4. Stress biomarker

    Hair cortisol concentraition (HCC), pg/mg hair

    Time frame: From enrollment to end of intervention (24 weeks)

  5. glucose

    fasted blood glucose (mM)

    Time frame: [Time Frame: From enrollment to end of intervention (24 weeks)]

  6. Insulin

    fasted plasma insulin (pmol/L)

    Time frame: [Time Frame: From enrollment to end of intervention (24 weeks)]

  7. blood lipids

    fasted blood lipids (mmol/L)

    Time frame: [Time Frame: From enrollment to end of intervention (24 weeks)]

  8. blood pressure

    Diastolic and systolic blood pressure in fasted state (mmHg)

    Time frame: [Time Frame: From enrollment to end of intervention (24 weeks)]

  9. circadian biomarker

    urinary melatonin (ng/mL)

    Time frame: [Time Frame: From enrollment to end of intervention (24 weeks)]

  10. Participant satisfaction and feasibility

    assessed using a study-specific questionnaire evaluating participants' experiences with the intervention content, delivery, usability, and perceived burden of the intervention

    Time frame: end of intervention (week 24)

06

Study locations

3 of 5 sites recruiting
  • Uni Bremen
    Bremen, Germany
    • U. Klink · Contact · 0049 421 218 68980
    Recruiting
  • TTZ
    Bremerhaven, Germany
    Not yet recruiting
  • Erasmus Medical Centre
    Rotterdam, Netherlands
    • H. Lammers-van der Holst · Contact · 0031 10 704 0704
    Recruiting
  • Wageningen University & Research
    Wageningen, Netherlands
    • M. Mensink · Contact · 0031 (0)317 480 100
    Recruiting
  • Lodz
    Lodz, Poland
    Not yet recruiting
07

References and documents

Related links

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT07631767
Lead sponsor
Wageningen University
Collaborators
University of Bremen, Medical University of Lodz, Erasmus Medical Center, Verein zur Förderung des Technologietransfers an der Hochschule Bremerhaven e.V.
Responsible party
Marco Mensink (assistant professor, Wageningen University) — Principal investigator
First posted
Jun 8, 2026
Start date
May 15, 2026
Primary completion
Jul 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Aug 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion